Pharvaris N.V. (PHVS)
USD 18.5
(0.05%)
USD 18.5
(0.05%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 252.27 Thousand | 150.18 Thousand | 80.45 Thousand | - | 547.41 | - |
| Gross Profit | -252.27 Thousand | -150.18 Thousand | -80.45 Thousand | - | -547.41 | - |
| Operating Expenses | 96.91 Million | 86.71 Million | 54.13 Million | 25 Million | 8.01 Million | 4.31 Million |
| Selling, General and Administrative Expenses | 31.33 Million | 29.33 Million | 18.34 Million | 5.49 Million | 2.32 Million | 668.12 Thousand |
| Research and Development Expenses | 65.57 Million | 57.37 Million | 35.78 Million | 19.5 Million | 5.68 Million | 3.64 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 96.91 Million | 86.71 Million | 54.13 Million | 25 Million | 8.01 Million | 4.31 Million |
| Operating Income | -96.91 Million | -86.73 Million | -65.89 Million | -25.01 Million | -7.99 Million | -4.31 Million |
| Interest Expense | 20.05 Thousand | 16.1 Thousand | 278.18 Thousand | 92.47 Thousand | - | - |
| Income Tax Expense | 1.04 Million | 679.08 Thousand | 70.11 Thousand | -83.25 Thousand | 16.88 Thousand | 380.00 |
| Earnings before Tax | -99.82 Million | -75.65 Million | -42.66 Million | -26.06 Million | -8.02 Million | -4.31 Million |
| Net Income | -100.87 Million | -76.33 Million | -42.73 Million | -25.98 Million | -8.04 Million | -4.31 Million |
| Earnings Per Share Basic | -2.63 | -2.27 | -1.41 | -0.85 | -1.66 | -0.14 |
| Earnings Per Share Diluted | -2.63 | -2.27 | -1.41 | -0.85 | -1.66 | -0.14 |
| Weighted Average Shares Outstanding | 38.39 Million | 33.58 Million | 30.41 Million | 30.51 Million | 4.85 Million | 31.83 Million |
| Weighted Average Shares Outstanding (Diluted) | 38.39 Million | 33.58 Million | 30.41 Million | 30.51 Million | 4.85 Million | 31.83 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -96.85 Million | -86.58 Million | -54.06 Million | -25 Million | -8 Million | -4.31 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 69.02 Thousand | 66.74 Thousand | 64.33 Thousand | 252.27 Thousand | 69.9 Thousand | 61.58 Thousand |
| Gross Profit | -69.02 Thousand | -66.74 Thousand | -64.33 Thousand | -252.27 Thousand | -69.9 Thousand | -61.58 Thousand |
| Operating Expenses | 34.48 Million | 28.31 Million | 26.41 Million | 94.67 Million | 26.2 Million | 1.37 Million |
| Selling, General and Administrative Expenses | 11.3 Million | 9.79 Million | 8.28 Million | - | 7.66 Million | 441.83 Thousand |
| Research and Development Expenses | 23.18 Million | 18.51 Million | 18.13 Million | - | 18.53 Million | 937.5 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 34.55 Million | 28.31 Million | 26.48 Million | 94.92 Million | 26.2 Million | 1.37 Million |
| Operating Income | -34.55 Million | -28.31 Million | -26.48 Million | -94.92 Million | -28.88 Million | -1.37 Million |
| Interest Expense | 9852.58 | - | 5309.19 | 20.05 Thousand | 4973.57 | 16 Thousand |
| Income Tax Expense | 70.98 Thousand | 285.11 Thousand | 728.51 Thousand | 1.02 Million | 146.27 Thousand | 33.52 Thousand |
| Earnings before Tax | -29.81 Million | -27.73 Million | -31.17 Million | -97.78 Million | -23.45 Million | 766.59 Thousand |
| Net Income | -29.88 Million | -28.01 Million | -31.9 Million | -98.8 Million | -23.59 Million | 733.07 Thousand |
| Earnings Per Share Basic | -0.55 | -0.52 | -0.61 | - | -0.58 | 0.02 |
| Earnings Per Share Diluted | -0.55 | -0.52 | -0.61 | - | -0.58 | 0.02 |
| Weighted Average Shares Outstanding | 53.93 Million | 53.81 Million | 52.29 Million | 38.39 Million | 40.9 Million | 34.55 Million |
| Weighted Average Shares Outstanding (Diluted) | 53.93 Million | 53.81 Million | 52.29 Million | 38.39 Million | 40.9 Million | 34.55 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -34.48 Million | -28.24 Million | -26.41 Million | - | -28.82 Million | -1.31 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
TI
LXCHEM
RXMD
RY4C
DOM
MAXHEALTH